Cite
HARVARD Citation
Gallagher, E. et al. (n.d.). Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).. Journal of clinical oncology. 40 (28), p. 422. [Online].